C4 Therapeutics

CCCCNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$407.213 M

$3.31 +0.30%

Close of 22 Sept 2026

Revenue

$35.9M

#2831 by revenue

Earnings

-$105.0M

Loss-making

Shares outstanding

123,025,136

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#73Zura BioZURA$432.2M
#74Cabaletta BioCABA$423.9M
#75C4 TherapeuticsCCCC$407.2M
#76Artiva BiotherapeuticsARTV$395.5M
#77AgenusAGEN$392.9M

What if C4 Therapeutics were worth as much as…

Open the what-if tool →

Gold $30.2T

$245,754.41

Per share 74,246× higher

Bitcoin $1.74T

$14,156.90

Per share 4,277× higher

Nvidia $5.52T

$44,834.47

Per share 13,545× higher

Or at a round number

$500.0M $1.00B $2.00B $5.00B

Where these numbers come from

Share counts and financials for C4 Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.